Covidien Seeks Participation In FDA-CMS Parallel Review Program
This article was originally published in The Gray Sheet
Executive Summary
The firm’s corporate chief medical officer Michael Tarnoff says Covidien is developing a standard-of-care-disrupting device that would gain from early formal attention by CMS; he hopes to hear from the agencies on acceptance for parallel review by year’s end. Tarnoff said he thinks the program is underutilized.
You may also be interested in...
Exact Sciences Colon Cancer Test Gets Quick Results From CMS
CMS granted the company a broad-based national coverage policy at breakneck speed and a positive preliminary payment decision to boot for the Cologuard DNA stool test. It is the first national coverage determination resulting from the FDA-CMS parallel review pilot.
CDRH Preps New Program To Streamline Approval-To-Reimbursement Path
The device center is in the very early stages of launching the “CDRH Reimbursement Program,” planning to go beyond its current parallel-review collaboration with CMS to work with device firms, CMS and private payers to streamline the pathway from market approval to reimbursement.
It’s A New World, Don’t Delay New Business Models, Market Observers Urge
Amplified message at AdvaMed 2013: Device firms must remake businesses to adapt to constrained resources and new market incentives.